# EDGAR Filing Document

**Accession Number:** 0001595353
**File Stem:** 0001493152-26-010843
**Filing Date:** 2026-3
**Character Count:** 5207
**Document Hash:** 982ac7890f60e51ef76a17e7dcd4f938
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-010843.hdr.sgml**: 20260415

**ACCESSION NUMBER**: 0001493152-26-010843

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Poshinski Amir
- **CENTRAL INDEX KEY:** 0001974114

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36345
- **FILM NUMBER:** 26765359

**MAIL ADDRESS:**
- **STREET 1:** 48 TZAHAL ST
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 00000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Galmed Pharmaceuticals Ltd.
- **CENTRAL INDEX KEY:** 0001595353
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981147233
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** C/O MEITAR LAW OFFICES
- **STREET 2:** 16 ABBA HILLEL SILVER RD.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250608
- **BUSINESS PHONE:** 97236938448

**MAIL ADDRESS:**
- **STREET 1:** C/O MEITAR LAW OFFICES
- **STREET 2:** 16 ABBA HILLEL SILVER RD.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250608

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Poshinski Amir<br><sub>(Last) (First) (Middle)</sub><br>C/O MEITAR LAW OFFICES *<br>16 ABBA HILLEL SILVER RD.<br><sub>(Street)</sub><br>RAMAT GAN,  5250608<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Galmed Pharmaceuticals Ltd. [ GLMD ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 11042 | D |  |
| Restricted Share Units | 1042<sup>(1)</sup> | D |  |
| Restricted Share Units | 11666<sup>(2)</sup> | D |  |
| Restricted Share Units | 12500<sup>(3)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Options to Purchase Ordinary Shares | 2021-07-15 | 2031-07-15 | Ordinary Shares | 111 | $558.00 | D |  |
| Options to Purchase Ordinary Shares | 2018-07-10 | 2028-07-10 | Ordinary Shares | 166 | $2080.80 | D |  |

---

### Footnotes:

(1) These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.

(2) These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

(3) These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

**Signature:** /s/ Amir Poshinski  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**